Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Scientific Officer | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.70 · Expires 2036-02-27 | Direct | 140,000 |
Reported balance
After 2026-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 140,000 · Balance 140,000 F1: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 3, 2026 23:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $35.70 | $0.00 |
DisclosureSEC source: 0001193125-26-089012 · ownership.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001193125-26-046881 · ownership.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 77,968 | $41.31 | $3,220,858.08 |
DisclosureSEC source: 0001193125-26-046881 · ownership.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,437 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 26, 2026. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 150,000 | $3.88 | $582,000.00 |
DisclosureSEC source: 0001193125-26-046881 · ownership.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $60.58 | $0.00 |
DisclosureSEC source: 0000950170-25-032730 · ownership.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-02-28 F1 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-25-020219 · ownership.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 85,176 | $68.11 | $5,801,337.36 |
DisclosureSEC source: 0000950170-25-020219 · ownership.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,405 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 18, 2025. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 150,000 | $3.29 | $493,500.00 |
DisclosureSEC source: 0000950170-25-020219 · ownership.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:31 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0000950170-24-091049 · ownership.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2024-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:31 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 34,773 | $37.94 | $1,319,287.62 |
DisclosureSEC source: 0000950170-24-091049 · ownership.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,581 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on September 11, 2024. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:31 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 60,000 | $2.81 | $168,600.00 |
DisclosureSEC source: 0000950170-24-091049 · ownership.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0000950170-24-014863 · ownership.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period. Read SEC document |
| January 08, 2024 Filed Jan 13, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0000950170-24-004343 · ownership.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 08, 2024 Filed Jan 13, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 29,792 | $27.46 | $818,088.32 |
DisclosureSEC source: 0000950170-24-004343 · ownership.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,354 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 6, 2024. Read SEC document |
| January 08, 2024 Filed Jan 13, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $3.02 | $151,000.00 |
DisclosureSEC source: 0000950170-24-004343 · ownership.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,455 | $30.89 | $631,752.68 |
DisclosureSEC source: 0000950170-23-042785 · ownership.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,146 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.85 to $30.99. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0000950170-23-040803 · ownership.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 29,545 | $30.48 | $900,531.60 |
DisclosureSEC source: 0000950170-23-040803 · ownership.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,601 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 6, 2024. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $3.02 | $151,000.00 |
DisclosureSEC source: 0000950170-23-040803 · ownership.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 01:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005176 · doc4.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-032305 · doc4.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 29,997 | $26.04 | $781,121.88 |
DisclosureSEC source: 0000899243-22-032305 · doc4.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,146 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on January 30, 2023. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $2.08 | $104,000.00 |
DisclosureSEC source: 0000899243-22-032305 · doc4.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 11, 2022 23:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000899243-22-005931 · doc4.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 2, 2022, so that the total number of shares subject to this option becomes fully vested and exercisable on February 2, 2026. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 22:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003573 · doc4.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 22:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 25,350 | $17.16 | $435,006.00 |
DisclosureSEC source: 0000899243-22-003573 · doc4.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,143 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 1, 2022. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 22:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 40,000 | $3.32 | $132,800.00 |
DisclosureSEC source: 0000899243-22-003573 · doc4.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 21:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000899243-21-028678 · doc4.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 21:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 30,482 | $20.59 | $627,624.38 |
DisclosureSEC source: 0000899243-21-028678 · doc4.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,493 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on August 9, 2021. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 21:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $2.89 | $144,500.00 |
DisclosureSEC source: 0000899243-21-028678 · doc4.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 22:18 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $29.41 | $0.00 |
DisclosureSEC source: 0000899243-21-005186 · doc4.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 5, 2021, so that the total number of shares subject to this option becomes fully vested and exercisable on February 5, 2025. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 21:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0000899243-20-032261 · doc4.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 21:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 31,225 | $22.88 | $714,428.00 |
DisclosureSEC source: 0000899243-20-032261 · doc4.xml · nonDerivative · entry 2 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,975 F1 · kind: The shares were withheld at the election of the Reporting Person as payment for the purchased shares and to satisfy tax withholding obligations in connection with the purchase of the shares. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 21:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $3.96 | $198,000.00 |
DisclosureSEC source: 0000899243-20-032261 · doc4.xml · nonDerivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 21:46 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0000899243-20-019201 · doc4.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-07-13 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of July 1, 2020, so that the total number of shares subject to this option becomes fully vested and exercisable on July 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.